<DOC>
	<DOCNO>NCT01941992</DOCNO>
	<brief_summary>The purpose study : - evaluate activity SAMITAL reduce incidence severe mucositis head-and-neck cancer patient undergo chemo-radiotherapy . - ass tolerability SAMITAL impact patient report outcome .</brief_summary>
	<brief_title>Role SAMITAL® Relief Chemo-radiation ( CT-RT ) Induced Oral Mucositis Head Neck Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Mucositis</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Stomatitis</mesh_term>
	<criteria>Histologically proven squamous cell carcinoma headandneck Eligible primary tumor site : oral cavity , oropharynx , larynx , hypopharynx Stage III IV disease without evidence distant metastases Patients candidate definitive concurrent chemoradiotherapy induction chemotherapy follow chemoradiotherapy Age ≥ 18 year Karnofsky Performance Status ≥70 Life expectancy ≥6 month Able swallow retain oral medication Good state dentition Patients must available treatment followup Confirmation adequate contraception use patient and/or partner Signed informed consent Previous radiotherapy oral cavity , and/or oropharynx , larynx , hypopharynx Serious comorbidities : uncontrolled heart disease , heart failure within 6 month prior study participation , history serious neurological and/or psychiatric abnormality . Chronic administration steroid immunosuppressant Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>head neck</keyword>
	<keyword>Squamous Cell Carcinoma</keyword>
	<keyword>oral mucositis</keyword>
	<keyword>Chemo-radiotherapy</keyword>
</DOC>